Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Calidi Biotherapeutics Inc. (CLDI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CLDI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $120
1 Year Target Price $120
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.02% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.15M USD | Price to earnings Ratio - | 1Y Target Price 120 |
Price to earnings Ratio - | 1Y Target Price 120 | ||
Volume (30-day avg) 1 | Beta 1.16 | 52 Weeks Range 1.54 - 46.68 | Updated Date 08/29/2025 |
52 Weeks Range 1.54 - 46.68 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date 2025-08-08 | When - | Estimate -0.21 | Actual -1.99 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -158.23% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7879149 | Price to Sales(TTM) 50.83 |
Enterprise Value 7879149 | Price to Sales(TTM) 50.83 | ||
Enterprise Value to Revenue 49.42 | Enterprise Value to EBITDA -1.64 | Shares Outstanding 5349210 | Shares Floating 2999510 |
Shares Outstanding 5349210 | Shares Floating 2999510 | ||
Percent Insiders 6.98 | Percent Institutions 4.45 |
Upturn AI SWOT
Calidi Biotherapeutics Inc.
Company Overview
History and Background
Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing oncolytic virotherapies. Founded in 2014, they aim to revolutionize the treatment of cancer with targeted and potent therapies. The company has achieved milestones in preclinical and clinical development, demonstrating the potential of their platform.
Core Business Areas
- Oncolytic Virotherapy Development: Developing and commercializing oncolytic viruses for cancer treatment.
Leadership and Structure
The company is led by a team of experienced executives and scientists with expertise in oncology and virology. The structure comprises research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- SuperArmored oncolytic adenovirus platform: Calidi's SuperArmored platform uses an adenovirus that is engineered to protect the therapeutic payloads from immune clearance, while enhancing tumor selective replication, allowing for longer intravenous half-life and greater oncolytic potency. This product is under clinical development. Competitors include companies with oncolytic virus therapies such as Amgen (T-VEC).
- Neurolytic oncolytic cell therapies: Calidi's Neurolytic platform uses cell-based delivery of oncolytic viruses. Tumor-penetrating autologous or allogeneic cells are loaded with oncolytic adenoviruses and systemically delivered to patients. This strategy overcomes the blood-brain barrier and enhances cancer cell killing. This product is under clinical development. Competitors include companies with cell-based cancer therapies like Novartis and Gilead.
Market Dynamics
Industry Overview
The oncolytic virus therapy market is rapidly growing, driven by the increasing prevalence of cancer and the need for more effective and targeted treatments.
Positioning
Calidi Biotherapeutics Inc. is positioned as an innovator in the oncolytic virotherapy space, with a focus on developing novel and differentiated therapies.
Total Addressable Market (TAM)
The TAM for oncolytic virus therapy is estimated to reach billions of USD annually. Calidi is positioning itself to capture a significant share of this market through its innovative technologies.
Upturn SWOT Analysis
Strengths
- Innovative oncolytic virotherapy platforms
- Strong intellectual property portfolio
- Experienced management team
- Potential for targeted cancer treatments
Weaknesses
- Limited financial resources
- Reliance on clinical trial outcomes
- Dependence on regulatory approvals
- Early stage of development
Opportunities
- Expanding into new cancer indications
- Partnering with larger pharmaceutical companies
- Securing additional funding
- Advancing clinical trials
Threats
- Competition from other biotechnology companies
- Clinical trial failures
- Regulatory hurdles
- Market adoption challenges
Competitors and Market Share
Key Competitors
- AMGN
- MRTX
- BNTX
Competitive Landscape
Calidi Biotherapeutics Inc. competes with other biotechnology companies developing oncolytic virotherapies. The company's competitive advantage lies in its innovative platforms and targeted approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage. Future growth depends on the successful development and commercialization of its products.
Future Projections: Future projections depend heavily on clinical trial outcomes and regulatory approvals. Analyst estimates are not widely available due to the company's recent public listing.
Recent Initiatives: Recent initiatives include advancing clinical trials of its oncolytic virotherapy candidates and securing partnerships.
Summary
Calidi Biotherapeutics is an early-stage company with innovative oncolytic virotherapy platforms. Its success hinges on favorable clinical trial results and regulatory approvals. Financial constraints and competition pose challenges, but strategic partnerships and expansion into new indications present opportunities. Overall the company's growth potential is uncertain and requires close monitoring.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Third-party market research reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise. The financial data relies on company provided information and may be incomplete.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Calidi Biotherapeutics Inc.
Exchange NYSE MKT | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-11-01 | CEO & Director Dr. Eric E. Poma Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.calidibio.com |
Full time employees 28 | Website https://www.calidibio.com | ||
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.